Matthew Campbell, MD, MS

Matthew Campbell, MD, MS, University of Texas MD Anderson Cancer Center

Articles by Matthew Campbell, MD, MS

Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion.
View More
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes.
Katy Beckermann, MD, PhDRenal Cell Carcinoma | February 25, 2025
Part one of the discussion covers adjuvant therapy in kidney cancer, patient selection, and balancing risks and benefits.
Vadim Koshkin, MDUrothelial Carcinoma | February 12, 2024
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | May 20, 2024
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | May 20, 2024
The impact of squamous and other histologies on outcomes with EV are dissected.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | May 20, 2024
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.